ESR1 and breast cancer: The PI3K–Akt pathway is a highly crucial pathway in cancer development,[40] with its alterations observed in more than 70% of breast tumors; thus, it represents a significant therapeutic target against BC.[41] Therefore, one of the potential therapeutic strategies against BC is to inhibit the estrogen signaling pathway (estrogen production blockage or ER function inhibition).